Long-Term Study of ML-007C-MA for Schizophrenia
This study is looking at the long-term safety and how well a drug called ML-007C-MA works for adults with schizophrenia. You might be able to join if you are between 18 and 65 years old and have a diagnosis of schizophrenia. The main goal is to see if ML-007C-MA is safe and tolerable over a long period, up to 52 weeks. This study is open to people who have recently been in a related study (ML-007C-MA-211) or those who are new to this treatment. The study aims to enroll about 500 participants, but its current recruitment status is unclear.
- Study design
- This is an open-label study, meaning both you and your doctors will know you are receiving ML-007C-MA. It aims to enroll about 500 participants.
- What's involved
- You would take ML-007C-MA twice a day for up to 52 weeks, starting from your first dose until the end of treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study assesses safety and tolerability from the initial dose through the end of treatment, which can be up to 52 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
At a glance
Conditions
Where it's being run
41 sites across 14 statesStudy leadership
- MapLight Therapeutics · STUDY_DIRECTOR · MapLight Therapeutics
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To assess the safety and tolerability of long-term ML-007C-MA administration in adult participants with schizophreniaFrom initial dose through end of treatment (up to 52 weeks)
using the incidence of TEAEs, TE-SAEs, and TEAEs leading to study discontinuation.